Advanced Solid Tumors RAINFOL-01
Study details
View study details on clinicaltrials.gov.
Locations
- Santa Barbara
Clinical trial FAQs
Information for patients and study volunteers, including frequently asked questions.
This is a Phase 1/2 study of Rina-S; also known as GEN1184, formerly known as PRO1184, a folate receptor alpha (FRα) targeted antibody-drug conjugate, to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of Rina-S in participants with selected locally advanced and/or metastatic solid tumors, including epithelial ovarian cancer, endometrial cancer, breast cancer, non-small cell lung cancer, and mesothelioma.
The study consists of multiple parts:
Part A: monotherapy cohorts
Part B: tumor-specific monotherapy dose-expansion cohorts
Part C: platinum-resistant ovarian cancer (PROC) cohort
Part D: combination therapy cohorts
Part F: a monotherapy endometrial cancer cohort
Participants will continue to receive study treatment until the first instance of disease progression, unacceptable toxicity, investigator decision, consent withdrawal, study termination by the Sponsor, pregnancy, or death.
Email us to enroll
Related clinical trials
View all clinical trials- Clinical trial
Neoadjuvant Gynecological Cancers CORT125134-557 BELLA
An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (BELLA)
Status: Open to Enrollment
- Clinical trial
Adjuvant Advance Ovarian Cancer FRAmework-01 J5E-MC-JZXB
FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.
Status: Open to Enrollment
- Clinical trial
Adjuvant Breast Cancer A012103 OptimiCE-PCR
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
Status: Open to Enrollment
- Clinical trial
Adjuvant Breast Cancer ER-pos/HER2-neg EA1242
A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment for High Anatomic Stage ER-pos/HER2-neg Breast Cancer With RS≤25 (RxFINE-Low)
Status: Open to Enrollment
- Clinical trial
Adjuvant Breast NRG-BR009
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)
Status: Open to Enrollment